Menu

Close

Sign InSign Out

Materials

Co-pay Cards & Patient Savings Offers

Request Samples

Hospital Products

Vaccines, Biologics & ​​​​​​​Small-molecule Medicines

Pfizer Oncology Together

Pfizer RxPathways

Events

Materials

Videos

Menu

Close

Efficacy

Phase III Study Primary Endpoints

Success in ISGA: Clear or ​​​​​​​almost clear

Study Design

Phase III Study Secondary Endpoints

ISGA clear or almost clear

Time to ISGA success

Phase III Study: Other Endpoints

Pruritus

Quality of life assessments

Infant Study: Exploratory efficacy Endpoints

ISGA clear or almost clear

%BSA, EASI & POEM

Safety Data

Phase III Study Adverse Reactions*

Pivotal trial & 48-week extension study
Adverse Reactions

Open-Label Safety Extension Study*

Open-Label Safety Extension Study Rescue ​​​​​​​Therapy Endpoint

Study design

Infant Safety Study**

Adverse Reactions

Study design and Demographics

Savings & Support

Events

Materials

Videos

Copay Cards

Cost and Coverage

  • Prescribing Information
  • Patient Information
  • Patient Site
  • EUCRISA Dosing

    EUCRISA can be applied to the skin anywhere on the face and body1

    EUCRISA is for topical use only and not for ophthalmic, oral, or intravaginal use1

    Apply a thin layer of EUCRISA twice daily to affected areas of the skin1

    Lorem ipsum dolor sit amet, consectetur adipiscing elit. Sed semper semper massa id venenatis. Nullam id mattis nibh. Sed quis ante mauris. Ut facilisis non leo in maximus. Praesent nec ipsum odio.

    View Products

    No limitations on duration of use1

    If signs and symptoms of hypersensitivity occur, discontinue EUCRISA immediately and initiate appropriate therapy

    EUCRISA was studied in pivotal trials for 29 days and in an open-label safety extension study for up to 48 weeks

    Studied as monotherapy in treatment-naïve and treatment-experienced patients2*

       *Patients involved in pivotal trials were not required to have received prior treatment for atopic dermatitis. Those who did went through a washout period before starting treatment with EUCRISA.2

    Mean BSA of 18.3% in pivotal trials2

    Can be used on all skin tones2

       *Patients involved in pivotal trials were not required to have received prior treatment for atopic dermatitis. Those who did went through a washout period before starting treatment with EUCRISA.2

     References
    1. EUCRISA® (crisaborole) Full Prescribing Information. December 2018.
    2. Data on file. Pfizer Inc., New York, NY.
    3. Eichenfield LF, et al. J Am Acad Dermatol. 2017;77(4):641-649.​​​​​​​​​​​​

    Patient Information

    Help your patients by setting expectations

    Download here

    ** This is an optional area where footnotes can live.

    Learn how the first and only nonsteroidal topical PDE4 inhibitor works within the skin1

    The specific mechanism(s) of action of crisaborole in atopic dermatitis is not well defined. PDE4=phosphodiesterase 4

    Learn more

    ** This is an optional area where footnotes can live.

    Copay Cards

    *Eligible patients pay as little as $10​​​​​​

    Terms and Conditions apply​​​​​​

    ​​​​* Patients enrolled in state or federally funded prescription insurance programs are not eligible to use this card. Savings up to $970 per tube. Annual savings up to $3,880. This card will be accepted only at participating pharmacies. This card is not health insurance.

    Download Copay cards

    ** This is an optional area where footnotes can live.

    Savings & Support Program

    A savings and support program for your patients to help them with their access to EUCRISA

    See resources

    ** This is an optional area where footnotes can live.

    Order Samples

    Register or sign in to check availability and request samples.

    Order now

    ** This is an optional area where footnotes can live.

    Contraindications

    EUCRISA is contraindicated in patients with known hypersensitivity to crisaborole or any component of the formulation.

    Warnings and Precautions

    Hypersensitivity reactions, including contact urticaria, have occurred in patients treated with EUCRISA and should be suspected in the event of severe pruritus, swelling, and erythema at the application site or at a distant site. Discontinue EUCRISA immediately and initiate appropriate therapy if signs and symptoms of hypersensitivity occur.

    Adverse Reactions

    The most common treatment-related adverse reaction occurring in clinical trials was application site pain, such as burning or stinging.

    Please see Full Prescribing Information and Patient Information

    EUCRISA is indicated for topical treatment of mild-to-moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.

    INDICATION

    EUCRISA (crisaborole) is indicated for topical treatment of mild‑to‑moderate atopic dermatitis in adult and pediatric patients 3 months of age and older.

    EUCRISA is for topical use only and is not for ophthalmic, oral, or intravaginal use. For more information, please view the full prescribing information here.

    Please see full Prescribing Information.

    OK. We'll need you to sign in before we can determine if you are aligned with a sales  representative. 

    If you select 'Yes', you will be required to enter your username and password in the sign-in form  that will appear over this window.  

    Would you like to sign in now?